Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity

SCHALLER D., GÜNDÜZ M. G., Zhang F. X., Zamponi G. W., WOLBER G.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.155, pp.1-12, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 155
  • Publication Date: 2018
  • Doi Number: 10.1016/j.ejmech.2018.05.032
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1-12
  • Keywords: 1,4-dihydropyridine, Hexahydroquinoline, Calcium channel, Whole cell patch clamp, Binding mechanism, Molecular modelling, CA2+ CHANNEL, DIHYDROPYRIDINE BINDING, MOLECULAR DETERMINANTS, RECEPTOR-SITE, MODEL, PHENYLALKYLAMINES, ANTAGONISTS, RESIDUES, AGONISTS
  • Hacettepe University Affiliated: Yes


Nifedipine and isradipine are prominent examples of calcium channel blockers with a 1,4-dihydropyridine (DHP) scaffold. Although successfully used in clinics since decades for the treatment of hypertension, the binding mechanism to their target, the L-type voltage-gated calcium channel Cav1.2, is still incompletely understood. Recently, novel DHP derivatives with a condensed ring system have been discovered that show distinct selectivity profiles to different calcium channel subtypes. This property renders this DHP class as a promising tool to achieve selectivity towards distinct calcium channel subtypes. In this study, we identified a common binding mode for prominent DHPs nifedipine and isradipine using docking and pharmacophore analysis that is also able to explain the structure-activity relationship of a small subseries of DHP derivatives with a condensed ring system. These findings were used to guide the synthesis of twenty-two novel DHPs. An extensive characterization using H-1 NMR, C-13 NMR, mass spectra and elemental analysis was followed by whole cell patch clamp assays for analyzing activity at Cav1.2 and Cav3.2. Two compounds were identified with significant activity against Cav1.2. Additionally, we identified four compounds active against Cav3.2 of which three were selective over Cav1.2. Novel binding modes were analyzed using docking and pharmacophore analysis as well as molecular dynamics simulations. (C) 2018 Elsevier Masson SAS. All rights reserved.